Advertisement

Analytical and Bioanalytical Chemistry

, Volume 410, Issue 9, pp 2275–2281 | Cite as

Analytical challenges in sports drug testing

  • Mario Thevis
  • Oliver Krug
  • Hans Geyer
  • Katja Walpurgis
  • Norbert Baume
  • Andreas Thomas
Feature Article

Abstract

Analytical chemistry represents a central aspect of doping controls. Routine sports drug testing approaches are primarily designed to address the question whether a prohibited substance is present in a doping control sample and whether prohibited methods (for example, blood transfusion or sample manipulation) have been conducted by an athlete. As some athletes have availed themselves of the substantial breadth of research and development in the pharmaceutical arena, proactive and preventive measures are required such as the early implementation of new drug candidates and corresponding metabolites into routine doping control assays, even though these drug candidates are to date not approved for human use. Beyond this, analytical data are also cornerstones of investigations into atypical or adverse analytical findings, where the overall picture provides ample reason for follow-up studies. Such studies have been of most diverse nature, and tailored approaches have been required to probe hypotheses and scenarios reported by the involved parties concerning the plausibility and consistency of statements and (analytical) facts. In order to outline the variety of challenges that doping control laboratories are facing besides providing optimal detection capabilities and analytical comprehensiveness, selected case vignettes involving the follow-up of unconventional adverse analytical findings, urine sample manipulation, drug/food contamination issues, and unexpected biotransformation reactions are thematized.

Keywords

Clenbuterol Proguanil Chlorazanil Manipulation Doping Mass spectrometry 

Notes

Acknowledgments

The authors thank the Manfred-Donike-Institute for Doping Analysis (Cologne, Germany) and the Federal Ministry of the Interior of the Federal Republic of Germany (Bonn, Germany) for the support.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    WADA. The 2018 Prohibited List. Montreal: Wolrd Anti-Doping Agency; 2017 [cited 26.10.2017]. Available from: https://www.wada-ama.org/sites/default/files/prohibited_list_2018_en.pdf.
  2. 2.
    Kidd B, Edelman R, Brownell S. Comparative analysis of doping scandals: Canada, Russia, and China. In: Wilson W, Derse E, editors. Doping in elite sport. Chamaign: Human Kinetics; 2001. p. 153–88.Google Scholar
  3. 3.
    Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang Y-C, Hatton CK. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun Mass Spectrom. 2004;18(12):1245–9.CrossRefGoogle Scholar
  4. 4.
    Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013;7(4):345–51.CrossRefGoogle Scholar
  5. 5.
    Grata E, Perrenoud L, Saugy M, Baume N. SARM-S4 and metabolites detection in sports drug testing: a case report. Forensic Sci Int. 2011;213(1–3):104–8.CrossRefGoogle Scholar
  6. 6.
    Thevis M, Volmer DA. Mass spectrometric studies on selective androgen receptor modulators (SARMs) using electron ionization and electrospray ionization/collision-induced dissociation. Eur J Mass Spectrom. 2017;23.  https://doi.org/10.1177/1469066717731228.
  7. 7.
    Cox HD, Eichner D. Detection of LGD-4033 and its metabolites in athlete urine samples. Drug Test Anal. 2017;9(1):127–34.CrossRefGoogle Scholar
  8. 8.
    McLaren R. The Independent Person 2nd Report: Richard McLaren; 2016 [cited 27.10.2017]. Available from: https://www.wada-ama.org/sites/default/files/resources/files/mclaren_report_part_ii_2.pdf.
  9. 9.
    Perrenoud L, Schweizer Grundisch C, Baume N, Saugy M, Nicoli R. Risk of false positive results to SARM S-4 in case of therapeutic use of antineoplastic/antiandrogen drug containing flutamide: a case study. Drug Test Anal. 2016;8(11–12):1109–13.CrossRefGoogle Scholar
  10. 10.
    Thevis M, Schänzer W. Detection of SARMs in doping control analysis. Mol Cell Endocrinol. 2017;in press;  https://doi.org/10.1016/j.mce.2017.01.040.
  11. 11.
    Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405–15.CrossRefGoogle Scholar
  12. 12.
    Billin AN. PPAR-beta/delta agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin Investig Drugs. 2008;17(10):1465–71.CrossRefGoogle Scholar
  13. 13.
    Thevis M, Möller I, Thomas A, Beuck S, Rodchenkov G, Bornatsch W, et al. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls. Anal Bioanal Chem. 2010;396(7):2479–91.CrossRefGoogle Scholar
  14. 14.
    Schmid H, Jelkmann W. Investigational therapies for renal disease-induced anemia. Expert Opin Investig Drugs. 2016;25(8):901–16.CrossRefGoogle Scholar
  15. 15.
    Eichner D, Van Wagoner RM, Brenner M, Chou J, Leigh S, Wright LR, et al. Implementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls. Drug Test Anal. 2017;  https://doi.org/10.1002/dta.2202.
  16. 16.
    Dib J, Mongongu C, Buisson C, Molina A, Schänzer W, Thuss U, et al. Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls. Drug Test Anal. 2017;9:61–7.CrossRefGoogle Scholar
  17. 17.
    Buisson C, Marchand A, Bailloux I, Lahaussois A, Martin L, Molina A. Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: investigation on a positive case. J Pharm Biomed Anal. 2016;121:181–7.CrossRefGoogle Scholar
  18. 18.
    CyclingNews. Kvasina positive for EPO stimulator at Fleche du Sud: CyclingNews; 2017 [cited 05–07-2017]. Available from: http://www.cyclingnews.com/news/kvasina-positive-for-epo-stimulator-at-fleche-du-sud/.
  19. 19.
    Walpurgis K, Thomas A, Vogel M, Reichel C, Geyer H, Schänzer W, et al. Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of western blotting and LC-HRMS. Drug Test Anal. 2016;8(11–12):1152–61.CrossRefGoogle Scholar
  20. 20.
    Reichel C, Gmeiner G, Thevis M. Antibody-based strategies for the detection of luspatercept (ACE-536) in human serum. Drug Test Anal. 2017;  https://doi.org/10.1002/dta.2302.
  21. 21.
    WADA. World Anti-Doping Code. Montreal: World Anti-Doping Agency; 2015 [cited 12–04-2016]. Available from: https://wada-main-prod.s3.amazonaws.com/resources/files/wada-2015-world-anti-doping-code.pdf.
  22. 22.
    Thevis M, Geyer L, Geyer H, Guddat S, Dvorak J, Butch A, et al. Adverse analytical findings with clenbuterol among U-17 soccer players attributed to food contamination issues. Drug Test Anal. 2013;5:372–6.CrossRefGoogle Scholar
  23. 23.
    Krumbholz A, Anielski P, Gfrerer L, Graw M, Geyer H, Schanzer W, et al. Statistical significance of hair analysis of clenbuterol to discriminate therapeutic use from contamination. Drug Test Anal. 2014;6(11–12):1108–16.CrossRefGoogle Scholar
  24. 24.
    Parr MK, Blokland MH, Liebetrau F, Schmidt AH, Meijer T, Stanic M, et al. Distinction of clenbuterol intake from drug or contaminated food of animal origin in a controlled administration trial—the potential of enantiomeric separation for doping control analysis. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2017;34(4):525–35.CrossRefGoogle Scholar
  25. 25.
    Helmlin H-J, Mürner A, Steiner S, Kamber M, Weber C, Geyer H, et al. Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination. Forensic Sci Int. 2016;267:166–72.CrossRefGoogle Scholar
  26. 26.
    USADA. U.S. Volleyball Athlete Alexandra Klineman Accepts Finding of No Fault for Anti-Doping Rule Violation Colorado Springs: U.S. Anti-Doping Agency; 2017 [cited 17–11-2017]. Available from: https://www.usada.org/alexandra-klineman-accepts-finding-no-fault/.
  27. 27.
    Thevis M, Geyer H, Thomas A, Tretzel L, Bailloux I, Buisson C, et al. Formation of the diuretic chlorazanil from the antimalarial drug proguanil—implications for sports drug testing. J Pharm Biomed Anal. 2015;115:208–13.CrossRefGoogle Scholar
  28. 28.
    Thevis M, Geyer H, Sigmund G, Schänzer W. Sports drug testing: analytical aspects of selected cases of suspected, purported, and proven urine manipulation. J Pharm Biomed Anal. 2012;57:26–32.CrossRefGoogle Scholar
  29. 29.
    Geyer H, Mareck U, Schänzer W, Donike M, editors. The cologne protocol to follow up high testosterone/epitestosterone ratios. Recent advances in doping analysis. Cologne: Sport und Buch Strauss; 1997.Google Scholar
  30. 30.
    Thevis M, Geyer H, Mareck U, Sigmund G, Henke J, Henke L, et al. Detection of manipulation in doping control urine sample collection: a multidisciplinary approach to determine identical urine samples. Anal Bioanal Chem. 2007;388:1539–43.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Mario Thevis
    • 1
    • 2
  • Oliver Krug
    • 1
    • 2
  • Hans Geyer
    • 1
    • 2
  • Katja Walpurgis
    • 1
  • Norbert Baume
    • 3
  • Andreas Thomas
    • 1
  1. 1.Center for Preventive Doping Research – Institute of BiochemistryGerman Sport University CologneCologneGermany
  2. 2.European Monitoring Center for Emerging Doping Agents (EuMoCEDA)Cologne/BonnGermany
  3. 3.Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Geneva and Lausanne, Centre Hospitalier Universitaire Vaudois and University of LausanneEpalingesSwitzerland

Personalised recommendations